Crizotinib, a multi-target tyrosine kinase inhibitor (TKI) with activity against MET, ALK, and ROS1, was approved by the US FDA in 2011 as a first-line therapy for metastatic ALK-positive NSCLC [62]. This evidence concerns the gene MET and non-small cell lung carcinoma.